vulolisib   Click here for help

GtoPdb Ligand ID: 12075

Synonyms: Example 22 [WO2021104146A1]
Compound class: Synthetic organic
Comment: We obtained the chemical structure for the INN 'vulolisib' from the WHO's proposed INN list 127 which was released on 21 July 2022. In the WHO document it is described as a phosphatidylinositol 3-kinase (PI3K) inhibitor and antineoplastic agent. This compound is claimed in patent WO2021104146A1, in which it is described as a PI3Kα-selective inhibitor, with antiproliferative activity against cancer cells that express mutated forms of PI3Kα [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 127.78
Molecular weight 423.12
XLogP 2.98
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES NC(=O)[C@@H](Nc1ccc2c(c1)OCCn1c2nc(c1)N1C(=O)SC[C@H]1C(F)F)C
Isomeric SMILES C[C@H](Nc1cc2c(cc1)c1nc(cn1CCO2)N1[C@@H](CSC1=O)C(F)F)C(=O)N
InChI InChI=1S/C18H19F2N5O3S/c1-9(16(21)26)22-10-2-3-11-13(6-10)28-5-4-24-7-14(23-17(11)24)25-12(15(19)20)8-29-18(25)27/h2-3,6-7,9,12,15,22H,4-5,8H2,1H3,(H2,21,26)/t9-,12-/m0/s1
InChI Key KEEKMOIRJUWKNK-CABZTGNLSA-N
References
1. Zhan X, Su L. (2021)
Three fused ring derivative-containing salt or crystal form and pharmaceutical composition thereof.
Patent number: WO2021104146A1. Assignee: Shanghai Hansen Biomedical Technology, Jiangsu Hansen Pharmaceutical Group. Priority date: 25/11/2019. Publication date: 03/06/2021.